Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target of Yen4,600.00. The company’s shares closed ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Our collaboration with Daiichi Sankyo is an exciting opportunity to unlock therapeutic access to new cell types, paving the way for precision treatments that can transform patient outcomes.” ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine. The purchase is contingent on approval of the shot formulated for the XBB.1. ...